The aims of the present study were to further our understanding of the mechanisms underlying the low tumour MRE11 protein expression seen in poorly responding bladder cancer patients, as potentially this could be exploited clinically, and to determine the level of control, relative to transcription. The gene discussed is MRE11; the disease is urinary bladder carcinoma.